Market Overview

UPDATE: ISI Group Initiates CVS Caremark at Overweight, $53.50 PT

Share:
Related CVS
Vaccine Business The Gateway To Drug Stores Providing Profitable Primary Healthcare
Amazon In The Pharmacy Space: Is There Anything To This Beyond The Headlines?
NWQ Managers Sells Pfizer, Viacom, Edison (GuruFocus)

ISI Group initiated its coverage on CVS Caremark (NYSE: CVS) with a rating of Overweight and a price target of $53.50.

ISI Group commented, "Our thesis for CVS is based on our view of continued share gain at the pharmacy given the success of Maintenance Choice and the continuation of the WAG/ESRX dispute, improved growth and profitability at Caremark as a result of innovative solutions and the streamlining initiative, and a very shareholder friendly approach to capital deployment and enhanced capital returns."

CVS Caremark closed at $46.90 on Wednesday.

Latest Ratings for CVS

DateFirmActionFromTo
Apr 2017Tigress FinancialInitiates Coverage OnBuy
Apr 2017Tigress FinancialInitiates Coverage OnBuy
Feb 2017BairdDowngradesOutperformNeutral

View More Analyst Ratings for CVS
View the Latest Analyst Ratings

Posted-In: ISI GroupAnalyst Color Initiation Intraday Update Analyst Ratings

 

Related Articles (CVS)

View Comments and Join the Discussion!